|
| Genes | [GRIN1](/genes/grin1), [GRIN2A](/genes/grin2a), [GRIN2B](/genes/grin2b) |
| UniProt | P35439 (GluN1), Q9UQF2 (GluN2A), Q9UQB8 (GluN2B) |
| Molecular Weight | ~180-220 kDa (heterotetramer) |
| Subcellular Localization | Postsynaptic density, [dendritic spines](/cell-types/dendritic-spines) |
| Protein Family | Ionotropic glutamate receptor family |
| Structure | 4-subunit transmembrane channel (2 GluN1 + 2 GluN2/3 subunits) |
| Brain Expression | [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus), Striatum (highest in excitatory synapses) |
NMDA receptors (N-methyl-D-aspartate receptors) are glutamate-gated ion channels critical for synaptic transmission, plasticity, and learning. These receptors are unique among ionotropic glutamate receptors in requiring both glutamate binding and membrane depolarization for activation, making them coincidence detectors for synaptic activity. NMDA receptors are central to most forms of synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD), processes fundamental to memory and cognition.
In neurodegenerative diseases, NMDA receptor dysfunction is a major contributor to excitotoxicity — the pathological overactivation of glutamate receptors leading to calcium overload and neuronal death. Both excessive activation and impaired function of NMDA receptors contribute to neurodegeneration in Alzheimer's disease, Parkinson's disease, and stroke.
NMDA receptors are heterotetramers composed of:
- GluN1 subunit (encoded by GRIN1): Required for functional channels
- GluN2A-D subunits (encoded by GRIN2A, GRIN2B, etc.): Modulate properties
- GluN3A-B subunits: Modulatory subunits
Key structural features:
- Agonist binding domains (S1-S2): Bind glutamate (on GluN2) and glycine/D-serine (on GluN1)
- Transmembrane domains (M1-M4): Form the ion channel pore
- C-terminal intracellular domains: Regulate trafficking, scaffolding, and signaling
- Polyamine block: Magnesium block requires depolarization to relieve
NMDA receptors mediate:
- Excitatory transmission: Major contributor to excitatory postsynaptic currents
- Calcium influx: Highly permeable to Ca2+ (unlike AMPA receptors)
- Voltage dependence: Magnesium block relieved by depolarization
- Kinetic properties: Slow activation and deactivation kinetics
NMDA receptors are required for:
- Long-term potentiation (LTP): Activity-dependent strengthening of synapses
- Long-term depression (LTD): Activity-dependent weakening
- Spine morphogenesis: Activity-dependent structural plasticity
- Learning and memory: Essential for hippocampal-dependent memory
NMDA receptor composition changes during development:
- Early development: Predominantly GluN2B-containing receptors
- Postnatal switch: Gradual shift toward GluN2A
- Adult: Mostly GluN2A/GluN2B heteromers
- Experience-dependent: Activity influences subunit composition
NMDA receptors in Alzheimer's disease:
- Excitotoxicity: Aβ oligomers potentiate NMDA-mediated Ca2+ influx
- Receptor trafficking: Aβ disrupts NMDA receptor localization
- Synaptic loss: Overactivation leads to spine elimination
- Tau effects: Tau potentiates NMDA receptor dysfunction
- Therapeutic targeting: NMDA antagonists (memantine) are approved AD treatment
In Parkinson's disease:
- Excitotoxic hypothesis: Glutamate overactivity contributes to PD progression
- STN overactivity: Subthalamic nucleus hyperactivity via NMDA receptors
- Dopaminergic protection: NMDA antagonists protect dopaminergic neurons
- Dyskinesia: NMDA receptors involved in L-DOPA-induced dyskinesia
¶ Stroke and Brain Injury
In ischemic injury:
- Excitotoxicity: Major contributor to post-stroke neuronal death
- Massive glutamate release: Ischemia triggers glutamate release
- Calcium overload: Excessive Ca2+ influx through NMDA receptors
- Therapeutic failure: NMDA antagonists failed in stroke trials due to side effects
NMDA receptors are major drug targets:
- Memantine: Low-affinity open-channel blocker (approved for AD)
- Ketamine: High-affinity antagonist (rapid antidepressant)
- Ifenprodil: GluN2B-selective antagonist
- D-Serine enhancers: Glycine site modulators
- Partial agonists: Glycine site partial agonists
- Traynelis et al., Glutamate receptor ion channels (2010)
- Hardingham & Bading, Synaptic versus extrasynaptic NMDA receptor signaling (2010)
- Parsons & Raymond, Extrasynaptic NMDA receptor involvement (2014)
- Li et al., NMDA receptors in Alzheimer's disease (2011)
- GRIN1 Gene — GluN1 subunit
- GRIN2A Gene — GluN2A subunit
- GRIN2B Gene — GluN2B subunit
- Glutamatergic Signaling — Pathway
- AMPA Receptor Protein — Related receptor
- Excitotoxicity — Related pathway